2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transfusion, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4550 Association of Bortezomib-based induction with outcomes after autologous hematopoietic cell transplantation for AL amyloidosis according to cardiac involvement: A CIBMTR analysis

Matthew P Dandan, DO, Jeet Patel, DO2, Gregory Collins3
1 Medical College of Wisconsin, Milwaukee, United States
2 University of Kansas-Olathe, Kansas City, United States
3 University of Florida College of Medicine-Jacksonville, Jacksonville, United States

Background: Cardiac involvement is the dominant prognostic factor in light chain (AL) amyloidosis and may influence use of bortezomib-based induction before autologous hematopoietic cell transplantation (auto-HCT). Whether cardiac involvement modifies the association between bortezomib induction and post-transplant hematologic response or survival is unknown.

Methods: We performed a secondary analysis of CIBMTR public dataset MM17-021, including 440 patients with AL amyloidosis who underwent auto-HCT from 2014-2018. Patients with unknown cardiac status (n=66) were excluded, leaving 374 available patients stratified as cardiac/bortezomib (n=154), cardiac/no bortezomib (n=71), no cardiac/bortezomib (n=91), and no cardiac/no bortezomib (n=58). Primary outcomes were any hematologic response (complete or partial response) and complete response (CR) at day 100; secondary outcomes were overall survival (OS) and day-100 mortality. Multivariable logistic regression evaluated response. A parsimonious Cox model evaluated OS using cardiac involvement, bortezomib induction, their interaction, age, Karnofsky performance status, and melphalan dose; HCT-CI and renal involvement were added in a sensitivity model. Complete-case sample sizes were 251 for any response, 259 for CR, 365 for the primary OS model, and 290 for the sensitivity model. Median follow-up was 24.4 months.

Results: Bortezomib induction was used in 68.4% of patients with cardiac involvement and 61.1% without cardiac involvement. Day-100 hematologic response occurred in 80.5% of cardiac/bortezomib versus 63.1% of cardiac/no-bortezomib patients and in 69.4% versus 62.7% of patients without cardiac involvement. CR rates were 22.1%, 17.4%, 15.1%, and 28.8%, respectively. No significant cardiac involvement-by-bortezomib interaction was detected for any response (OR 1.95, 95% CI 0.62-6.16; P=0.256), CR (OR 3.11, 95% CI 0.81-11.94; P=0.098), or OS (HR 1.07, 95% CI 0.26-4.34; P=0.926). The OS result was consistent in the sensitivity model. Older age (HR 1.06 per year, 95% CI 1.01-1.11; P=0.016) and poor performance status (HR 2.47, 95% CI 1.19-5.14; P=0.016) were associated with inferior OS, whereas higher melphalan dose was associated with improved OS (HR 0.69 per dose level, 95% CI 0.51-0.93; P=0.016). Higher HCT-CI was associated with lower odds of CR in the sensitivity model (OR 0.76, 95% CI 0.58-0.99; P=0.044). Day-100 mortality was 2.7% (10/373) and was summarized descriptively because of limited events.

Conclusions: Among transplant-eligible patients with AL amyloidosis, no statistically significant effect modification by cardiac involvement was detected for the association between bortezomib-based induction and day-100 hematologic response or OS. Older age, poor performance status, and lower melphalan dose intensity were associated with inferior OS. Cardiac disease severity was unavailable, and wide interaction confidence intervals, missing response data, and residual confounding by patient fitness and treatment selection limit causal interpretation.

1Acknowledgment: The original data setwas collected by the Center for International Blood and Marrow Transplant Research (CIBMTR) which is supported primarily by the Public Health Service U24CA076518 from the National Cancer Institute; the National Heart, Lung, and Blood Institute; the National Institute of Allergy and Infectious Diseases; 75R60222C00011 from the Health Resources and Services Administration; NMDP; and the Medical College of Wisconsin. We acknowledge the CIBMTR staff for making the dataset publicly available. CIBMTR had no role in the study design, data analysis, interpretation of results, or manuscript preparation. The study was not reviewed by CIBMTR and does not represent its views.

Jeet Patel, DO: No relevant conflicts of interest to declare.